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Summary
 
Two subsets of murine splenic dendritic cells, derived from distinct precursors, can be distin-
guished by surface expression of CD8
 
a
 
 homodimers. The functions of the two subsets remain
controversial, although it has been suggested that the lymphoid-derived (CD8
 
a
 
1
 
) subset in-
duces tolerance, whereas the myeloid-derived (CD8
 
a
 
2
 
) subset has been shown to prime naive
T cells and to generate memory responses. To study their capacity to prime or tolerize naive
CD4
 
1
 
 T cells in vivo, purified CD8
 
a
 
1
 
 or CD8
 
a
 
2
 
 dendritic cells were injected subcutaneously
into normal mice. In contrast to CD8
 
a
 
2
 
 dendritic cells, the CD8
 
a
 
1
 
 fraction failed to traffic to
the draining lymph node and did not generate responses to intravenous peptide. However, af-
ter in vitro pulsing with peptide, strong in vivo T cell responses to purified CD8
 
a
 
1
 
 dendritic
cells could be detected. Such responses may have been initiated via transfer of peptide–major
histocompatibility complex complexes to migratory host CD8
 
a
 
2
 
 dendritic cells after injection.
These data suggest that correlation of T helper cell type 1 (Th1) and Th2 priming with injec-
tion of CD8
 
a
 
1
 
 and CD8
 
a
 
2
 
 dendritic cells, respectively, may not result from direct T cell acti-
vation by lymphoid versus myeloid dendritic cells, but rather from indirect modification of the
response to immunogenic CD8
 
a
 
2
 
 dendritic cells by CD8
 
a
 
1
 
 dendritic cells.
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A
 
ppropriate induction of tolerance and immunity
(memory) is a crucial function of the normal immune
system. The discovery of a novel subset of dendritic cells
(DCs) derived from a common lymphoid precursor (1) and
located in the thymic medulla and the T cell zones of sec-
ondary lymphoid tissue (2), together with preliminary in
vitro functional data (3, 4), has led to the suggestion that
such lymphoid DCs (LDCs) may be responsible for generat-
ing tolerance in naive T cell populations (5, 6). We have re-
cently proposed an evolutionary model of self/non-self dis-
crimination (7) in which LDCs are postulated to induce
deletional tolerance to self-antigens by means of preferential
internalization and presentation of self-antigen via receptors
recognizing the characteristic chemical structures generated
by self–biosynthetic enzymes. In contrast, myeloid DCs
(MDCs) are already known to express a number of “pattern
recognition receptors” (8) that recognize the biosynthetic
footprints of foreign organisms, and to stimulate naive T
cells in such a way as to generate T cell memory (9–11).
As an experimental test of whether LDCs and MDCs in-
duce distinct in vivo responses in naive T cells, splenic DCs
were fractionated on the basis of CD8
 
a
 
 expression, which
has been defined as a marker capable of distinguishing
splenic LDCs and MDCs in the mouse (2). A novel ap-
proach (6) was used in an attempt to ensure that only the
injected DCs were capable of presenting the test antigen, a
peptide of moth cytochrome 
 
c
 
 which is known to bind to
IE but not IA molecules. By injecting IE
 
1
 
 DCs into a host
that expressed IE only in the thymus, peptide presentation
was restricted to the adoptively transferred APCs, to which
the host T cells were nonetheless tolerant as a result of neg-
ative selection to IE in the thymus. Adoptive transfer of a
cohort of purified moth cytochrome 
 
c
 
 (MCC)-specific na-
ive T cells provided a sensitive detection system for presen-
tation of MCC peptide in vivo.
Surprisingly, we found no evidence that CD8
 
a
 
1
 
 DCs
migrated into the draining lymph nodes (DLNs) after sub-
cutaneous injection. Nonetheless, peptide-pulsed, sorted
CD8
 
a
 
1
 
 DCs were able to stimulate a significant T cell re-
sponse. As expected, donor-derived CD8
 
a
 
2
 
 DCs were
found in the DLNs and also stimulated T cell division.
These data suggest an alternative interpretation of recent
experiments in which subcutaneous injection of antigen-
pulsed LDCs was shown to induce Th1 priming, whereas
MDCs biased the response towards Th2 unless IL-12 was
coinjected (12, 13). 
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Materials and Methods
 
Experimental Animals.
 
Transgenic (Tg) mouse lines were bred
and housed under specific pathogen–free conditions at the Cen-
tenary Institute Animal Facility. Approval for all animal experi-
mentation was obtained from the Institutional Ethics Committee
at the University of Sydney. 107-1 and 36-2 lines of IE
 
a
 
d
 
 Tg
mice (14, 15) were originally the gift of D. Lo (Scripps Research
Institute, La Jolla, CA). The -D line TCR Tg line expressing the
5C.C7 receptor, which recognizes the COOH-terminal epitope
of MCC in the context of IE
 
a
 
k
 
b
 
k
 
, IE
 
a
 
k
 
b
 
b
 
, or IE
 
a
 
d
 
b
 
b
 
 (16, 17),
was maintained on a C57BL/6 background and crossed with
107-1 to provide double Tg offspring for use in experiments. In
some experiments, donor DCs were derived from (107-1 
 
3
 
B6.SJLPtprc
 
a
 
)F
 
1
 
 mice, to introduce the Ly5.1 allele used to track
cells in vivo.
 
T Cell Purification, Labeling, and Injection.
 
Pooled inguinal, ax-
illary, subscapular, cervical, and paraaortic LNs of naive (TCR 
 
3
 
107-1) mice served as the source of MCC-specific T cells. Puri-
fied T cells were prepared from single cell suspensions and labeled
with 5-carboxy fluorescein succinimidyl ester (CFSE) as de-
scribed previously (18). 10
 
7
 
 T cells were injected into the lateral
tail vein of unirradiated mice 2 d before injection of DCs.
 
DC Purification, Labeling, and Injection.
 
A modification of the
protocol of Vremec and Shortman (19) was used to purify splenic
DCs. Digestion with collagenase/EDTA and density centrifuga-
tion (
 
r
 
 
 
5
 
 1.077) was followed by a two-step positive magnetic
bead selection, replacing the negative selection/FACS
 
®
 
 sorting
steps in the original protocol. Thus, CD11c positive selection was
performed using mAb N418 (20), anti–hamster FITC (Caltag),
and anti-FITC Multisort microbeads (Miltenyi Biotec) followed
by passage over a MACS
 
®
 
 column (Miltenyi Biotec). The beads
were removed by enzyme digestion, and a further positive selec-
tion for expression of CD8
 
a
 
 was performed using anti-CD8
 
a
 
–
coupled microbeads (Miltenyi Biotech) and a further MACS
 
®
 
column passage. Because this protocol failed to achieve 
 
.
 
70%
purity of CD8
 
a
 
1
 
 cells, FACS
 
®
 
 sorting for CD11c
 
1
 
CD8
 
a
 
 posi-
tive and negative populations was substituted for the final CD8
 
a
 
bead selection in some experiments.
For peptide-pulsing, DCs were incubated in tissue culture me-
dium (TCM; reference 18) containing 1 
 
m
 
M MCC
 
87–103
 
 peptide
(Chiron Mimotopes) for 2 h at 37
 
8
 
C, then washed twice before
injection. DCs (1–7 
 
3
 
 10
 
5
 
) were injected subcutaneously into
one hind footpad of each recipient mouse. Alternatively, recipi-
ents were immunized with 20 
 
m
 
g MCC
 
87–103
 
 peptide by injection
into the lateral tail vein 12 h after DC administration.
In some experiments, DCs were labeled with 5-chlorometh-
ylfluorescein diacetate (CMFDA; Molecular Probes) before in-
jection. Labeling was performed by resuspending cells at 10
 
7
 
cells/ml in TCM, incubating with 2 
 
m
 
m CMFDA for 15 min at
37
 
8
 
C, then washing and incubating in fresh TCM for an addi-
tional 30 min at 37
 
8
 
C. Cells were then washed twice before in-
jection.
 
Flow Cytometry.
 
Five color antibody staining was performed as
described previously for analysis of CFSE-labeled T cells (18). For
detection of CMFDA-labeled DCs in DLNs, individual popliteal
LNs were digested in collagenase/EDTA, as for spleen. A combi-
nation of anti-Ly5.1 (biotinylated A20.1 [provided by E.A. Boyse,
Memorial Sloan-Kettering Cancer Center, New York] plus allo-
phycocyanin-conjugated streptavidin), anti-CD11c (N418 super-
natant plus anti–hamster Texas red [Caltag]), and CMFDA fluores-
cence was used to distinguish donor-derived DCs. Expression of
CD8
 
a
 
 was detected with PE-conjugated anti-CD8
 
a
 
 (Caltag).
7-channel data acquisition (0.5–1 
 
3
 
 10
 
6
 
 events per sample)
 
was performed on a FACStarPLUS
 
®
 
 flow cytometer (Becton
Dickinson) and analyzed using FlowJo software (Treestar).
 
Results and Discussion
 
Functional Responses of Antigen-specific T Cells to Subcutane-
ously Injected DCs.
 
The experimental protocol, designed
to limit antigen presentation to the DC subset of interest,
made use of a pair of MHC Tg lines in which IE
 
a
 
d
 
 was ex-
pressed on the H-2
 
b
 
 background, allowing it to pair with
endogenous IE
 
b
 
b
 
 to form a functional IE molecule capable
of presenting MCC
 
87–103
 
 peptide to naive Tg T cells ex-
pressing the 5C.C7 TCR. Mice from the 36-2 line (14, 15),
which expresses IE
 
a
 
d
 
 only in the thymus, were used as hosts
of adoptively transferred purified responder T cells and of
subcutaneously injected DCs. Mice from the 107-1 line (14,
15), in which IE
 
a
 
d
 
 is expressed with a wild-type distribu-
tion, served both as direct DC donors in the functional
experiments and as parents of (107-1 
 
3
 
 B6.SJLPtprc
 
a
 
)F
 
1
 
donors of Ly5.1
 
1
 
 DCs and (TCR Tg 
 
3
 
 107-1)F
 
1
 
 donors of
T cells.
To test the capacity of subcutaneously injected DCs to
migrate to the DLNs and act as APCs presenting intrave-
nously administered peptide to naive T cells, CD8
 
a
 
2
 
 and
CD8
 
a
 
1
 
 DCs were purified from the spleens of 107-1 Tg
donors by two-step positive magnetic bead selection, first
for expression of CD11c and then for CD8
 
a
 
. This yielded
two fractions, a CD8
 
a
 
2
 
 fraction containing 
 
,
 
1% CD8
 
a
 
1
 
contaminants, and a “CD8
 
a
 
1
 
” fraction containing 50%
CD8
 
a
 
2
 
 cells and 50% CD8
 
a
 
2
 
 cells. An aliquot of each pu-
rified fraction was pulsed with peptide in vitro. The DCs
were then injected into hind footpads of unirradiated 36-2
Tg mice reconstituted with CFSE-labeled T cells 2 d be-
fore. 12 h after DC injection, MCC
 
87–103
 
 peptide was ad-
ministered intravenously to the animals that had received
unpulsed DCs, and antigen-specific T cell responses were
determined 3 d later in the popliteal LNs. The marked in-
crease in effectiveness of in vitro versus in vivo peptide
loading was apparent from comparison of responses in the
two groups (Fig. 1, A vs. B). We have previously noted a
difference of similar magnitude between in vitro and in
vivo peptide loading of naive B cells (6). The size of the re-
sponse to intravenous peptide correlated with the number
of CD8
 
a
 
2
 
 DCs in the inoculum, being barely detectable in
the group that received the “CD8
 
a
 
1
 
” DCs consisting of a
mixture of CD8
 
a
 
2
 
 and CD8
 
a
 
1
 
 DCs, and highest in the
animals receiving a high dose of pure CD8
 
a
 
2
 
 DCs (Fig.
1 A). The response to both fractions of peptide-pulsed DCs
was high. Analysis of the CFSE division profiles indicated
that the number of cells recruited into division was again
proportional to the number of CD8
 
a
 
2
 
 cells in the inocu-
lum (Fig. 1 B, bottom panels). As expected, all the T cell
responses were localized to the DLNs, as indicated by the
lack of response in the contralateral popliteal node.
Because of difficulties in achieving sufficient DC purity
in the experiment described above, CD11c
 
1
 
 DCs obtained
by positive bead selection were sorted on the basis of CD8
 
a 
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expression, yielding a CD8
 
a
 
2 fraction with ,0.01% con-
taminating CD8a1 cells, and a CD8a1 fraction contami-
nated with 1.0% CD8a2 cells. After peptide pulsing, the
cells were injected into the hind footpads of 36-2 mice.
Once again, the response to CD8a2 cells was marginally
higher, as indicated by stimulation of one more T cell divi-
sion than was seen in the response to CD8a1 cells (Fig.
2 A). As expected, expression of the activation markers
CD69 and CD44 was increased before the first cell division
(Fig. 2 B), and the pattern of CD69 downregulation was
consistent with previous data derived from direct peptide
administration to TCR Tg mice (Smith, A.L., and B. Faze-
kas de St. Groth, manuscript in preparation).
Detection of Subcutaneously Injected DCs in the DLNs.
Tracking CMFDA-labeled DCs purified using the two
methods described above indicated a very striking result,
namely that the donor DCs isolated from the DLNs 22 h
after inoculation were uniformly CD8a2 (Fig. 3). The ab-
sence of donor-derived CD8a1 DCs in the DLNs could
have resulted either from downregulation of CD8a by the
inoculated CD8a1 DCs, or from failure of the CD8a1
DCs to migrate to the DLNs. The correlation between the
number of CD8a2 DCs in the inoculum and in the DLNs
indicated that the latter was the more likely explanation.
However, the disparity between the substantial T cell re-
sponse to peptide-pulsed, sorted CD8a1 DCs (Fig. 2) and
the tiny number of donor-derived DCs isolated from the
DLNs (Fig. 3 B) also suggested that antigen may have been
transferred from donor to host cells after injection. Since
simple peptide transfer from donor to host cells was ex-
cluded by the experimental protocol (Fig. 1), any antigen
transfer from donor cells must have involved transfer of
both peptide and MHC, presumably as a complex formed
during in vitro pulsing. This type of peptide/MHC transfer
between DCs has recently been documented in vitro (21),
Figure 1. Local response of
CFSE-labeled T cells to (A) in-
travenous peptide or (B) in
vitro–pulsed peptide, after sub-
cutaneous inoculation of DCs
purifed using MACS® beads.
The total numbers of CD11c1
DCs in the inocula were 6 3 105
“CD81” (3.0 3 105 CD81 plus
3.0 3 105 CD82), 6.5 3 105
CD82 (6.2 3 105 CD82 plus
0.3 3 105 CD81), and 12.0 3
105 CD82 (high dose; 11.4 3
105 CD82 plus 0.6 3 105
CD81). Popliteal LN cells were
gated for CD41 propidium io-
dide (PI)2 cells. The data are
presented as 10% probability
plots plus outliers. The histo-
grams (B, bottom panels) show
CFSE division peaks within the
CD41PI2Tga1 T cell gate
(boxed). Note the different his-
togram scales, indicating signifi-
cantly different responses in the
different groups.
Figure 2. Local response of CFSE-labeled T cells to in vitro–pulsed
peptide after subcutaneous inoculation of sorted DCs. The total numbers
of CD11c1 DCs in the inocula were 2.5 3 105 CD81 (2.5 3 105 CD81
plus 0.03 3 105 CD82) and 3.0 3 105 CD82 (no detectable CD81). (A)
Popliteal LN cells were gated for CD41PI2 cells. The data are presented
as 10% probability plots plus outliers. (B) Dot plots of CFSE versus CD69
or CD44 expression within the CD41PI2Tga1 T cell gate (boxed in A).596 Dendritic Cell Homing
and may account for previous reports in which thymic DCs
presented endogenous self-antigen–MHC complexes syn-
thesized by epithelial cells (22). It could also account for
the phenomenon of cross-presentation of MHC class I
molecules in the DLNs (23–25), a mechanism that is essen-
tial to ensure that viruses do not escape immune surveil-
lance merely by failing to infect the APCs required for
priming cytotoxic T cells.
Functional Capabilities of LDCs In Vivo. These data sug-
gest an alternative interpretation of recent experiments
characterizing the response of naive T cells to antigen-
pulsed purified DC subpopulations (12, 13). These experi-
ments have been interpreted to indicate that lymphoid
DCs, purified on the basis either of CD8a expression (12)
or of failure to express CD11b at high levels (13), migrate
to DLNs after subcutaneous administration and generate
preferential priming of a Th1 phenotype by means of their
high levels of IL-12 production. In contrast, MDCs (CD8a2,
CD11bhi) were suggested to prime for a Th2 response.
However, in light of our finding that no CD8a1 DCs of
donor phenotype could be found in the DLNs after subcu-
taneous injection, we suggest that priming for both Th1
and Th2 memory results from direct stimulation of naive T
cells by MDCs that have migrated to the DLNs, with the
differential outcomes conditional upon the cytokine envi-
ronment and/or the amount of available antigen, which
will differ depending on the constituents of the original in-
oculum. This interpretation is supported by the data of
Maldonado et al. (12), demonstrating that injection of
parenteral IL-12 stimulates T cell production of IFN-g
rather than IL-4 in response to subcutaneous injection of
MDCs. Thus, when LDCs are injected subcutaneously, it is
possible that IL-12 production at the site of injection may
influence the ability of MDCs to induce Th1 development
in the DLNs, without the LDCs playing any direct role in
antigen presentation to naive T cells in the node. Shift in
the Th1/Th2 balance of the response to soluble subcutane-
ous antigen after administration of Flt3 ligand (which pref-
erentially expands the LDC population in vivo) versus
GM-CSF (which increases only MDC numbers) (13), is
also consistent with this interpretation. In addition, if pep-
tide–MHC is transferred from LDCs to MDCs (either do-
nor- or host-derived) before their migration to the DLNs,
the concentration of antigen to which T cells are exposed
could change dramatically, which has previously been
demonstrated to influence the Th1/Th2 balance after in
vitro priming (26).
These experiments do not directly address the physiolog-
ical role of LDCs resident in the T cell zones of secondary
lymphoid tissue. However, they are consistent with a
model in which LDCs are generated in situ from precursors
within the thymus (1) and secondary lymphoid tissue (27)
Figure 3. Detection of
CMFDA-labeled DCs in the
DLNs 22 h after subcutaneous
inoculation. DCs were first de-
tected in the DLNs 17 h after in-
oculation, and were undetectable
2 d later (not shown). The total
numbers of CD11c1 DCs in the
inocula were as follows: (A) 8.8 3
105 “CD81” purifed using
MACS® beads (4.1 3 105 CD81
plus 4.7 3 105 CD82) and 9.7 3
105 CD82 (9.7 3 105 CD82 plus
0.025  3 105 CD81); and (B)
1.0 3 105 CD81 (1.0 3 105
CD81 plus 0.025 3 105 CD82),
of which a total of 0.059 6
0.0013% were recovered from
the DLNs, and 6.0 3 105 CD82
(no detectable CD81), of which
0.31 6 0.036% were recovered
from the DLNs. Transfer of 2.5 3
105 CD81 (2.5 3 105 CD81 plus
0.05 3 105 CD82, not shown)
allowed recovery of 0.072%
from the DLNs. The figures in
the lower right of each panel
show the number (6 SEM) of
donor-derived DCs as a percent-
age of total host DCs in the
DLNs.597 Smith and Fazekas de St. Groth Brief Definitive Report
and comprise a sedentary population which, in contrast to
MDCs, relies on mechanisms other than migration from
the periphery to capture antigen for presentation to T cells
within the T cell zone (7). It has been suggested that LDCs
induce deletional tolerance (3, 5, 6, 7). Our unpublished
data, derived from comparison of the deletional response of
naive peripheral CD41 T cells to either intravenous pep-
tide or a transgenic neoself-antigen, suggest that induction
of deletional tolerance is accompanied by very early pro-
duction of Th1 (IL-2, IL-3, IFN-g) but not Th2 cytokines
(IL-4 or IL-10), consistent with the high level of IL-12
production by stimulated LDCs (28). Whether Th1 immu-
nogenic (memory) responses to foreign antigen are induced
by direct presentation to T cells by a combination of LDCs
and MDCs (29), or whether LDCs play only an indirect
role in induction of memory responses, namely as cytokine
producers but not APCs, remains to be elucidated.
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